Biotech API Surging Worldwide
“Geographies across the globe are showing insurgent growth in the Biotech API industry”, says RNCOS.
The global biotech API will see growth in its biogeneric API business driven in particular by the loss of patent protection of several blockbuster biotech drugs in near future. The market is also expected to see robust usage and popularity of biosimilars, especially erythropoietin, recombinant human insulin amongst others. At the competitive front, players, such as Bayer Pharma AG, Biocon Limited, Boehringer Ingelheim, Hospira amongst others are leading the biotech API market. These competitors are riding on their core biotech strengths and expanding their biotech API capabilities with active research and innovation activity. RNCOS expects the worldwide API market size to be likely to register a healthy CAGR of around 8% during 2012-2015.
The report spread in over 55 pages provides a proper understanding of the API market globally along with an idea about its current state. The key industry drivers have been covered in details along with the current and future market projections for the time period of 2012-2015. The major segments and sub-segments of the API Industry have been covered along with the description of the API industry in the most promising geographies of India, China, Italy and Taiwan. The report also analyzes the opportunity assessment for companies in the global APIs market in terms of therapeutic segments and countries’ comparative index. An analysis of the emerging areas, competitive landscape, and regulatory stringency further provides a holistic understanding of the global API market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM424.htm
Some of our Related Reports are:
- Interferon Market Forecast to 2015 (http://www.rncos.com/Report/IM431.htm)
- Insulin Market Forecast to 2015 (http://www.rncos.com/Report/IM430.htm)
- Human Growth Hormone Market Forecast to 2015 (http://www.rncos.com/Report/IM429.htm)
- Erythropoietin Market Forecast to 2015 (http://www.rncos.com/Report/IM428.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
B-129, Sector 6 Noida - 201301
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biotech API Surging Worldwide here
News-ID: 249142 • Views: 2011
More Releases from RNCOS E-Services Pvt. Ltd.
Malaysia Convenience Store Witnessing Tremendous Growth
“Rapid expansion plans of major convenience stores in Malaysia such as 7-Eleve and 99 Speed Mart are expected to drive the market.” says RNCOS Malaysia Convenience store has been witnessing a tremendous growth in the retail industry. Key players in the country are widening their foot prints in retail industry by innovatively increasing the product portfolio as per the consumer behavior and increasing the number of stores. There is a cut
Growing Opportunity in the Global Enterprise Software Market
“Increasing adoption of enterprise resource management software, customer relationship management software and human resource management software is expected to drive the Global Enterprise Software market.” Says RNCOS The global enterprise software market has reported a significant growth in the recent years and is presenting ample opportunities to the industry’s players. With increasing global competition and rising awareness regarding enterprises software across the globe, the worldwide enterprise software market is poised to
Global Wearable Medical Device Market Outlook 2020
By wearable medical devices we understand non-invasive, autonomous health tools, which aid in clinical monitoring beyond the hospitals. The application of wearable ranges from monitoring glucose levels in blood to managing chronic diseases such as heart diseases, asthma and diabetes. These devices generally provide non-invasive sensing, local processing, user feedback, and communication capabilities. In the latest report “Global Wearable Medical Device Market Outlook 2020”, RNCOS’ analysts have endeavored to
Global Point-of-Care Diagnostics Market Outlook 2020
It is widely accepted that disease prevention and risk-reduction strategies have the potential to lower disease burden as well as improve the overall health of individuals. POCT technology offers such potential for diagnosis and treatment of patients, as it facilitates rapid availability of test results and hence, early clinical decision making and intervention. Amidst a rising disease incidence, reduced budget, growing focus towards personalization of care, and ever-increasing integration of
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
XING releases API preview
Hamburg, March 23, 2007 - OPEN Business Club AG has launched a closed API preview for its global business networking platform XING (www.xing.com). The XML based interface is designed to allow other programs to interact with the XING system. When the API is completed an open beta-phase is planned for later this year. XING is making an API (Application Programming Interface) available as a web service for XING members to have